Atypical hydroa vacciniforme-like epstein-barr virus associated T/NK-cell lymphoproliferative disorder

American Journal of Dermatopathology

Volumn 34, Issue 8, 2012, Pages

  Lee, Hye Young ^a   Baek, Jin Ok ^a   Lee, Jong Rok ^a   Park, Sang Hui ^a   Jeon, In Sang ^a   Roh, Joo Young ^a  

^a Gachon University   (South Korea)

Author keywords

Atypical hydroa vacciniforme; Epstein Barr virus; T NK cell lymphoproliferative disorder

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE; VIRUS CAPSID ANTIGEN;

ABDOMINAL PAIN; ARTICLE; CASE REPORT; CHILD; EPSTEIN BARR VIRUS ASSOCIATED NATURAL KILLER CELL LYMPHOPROLIFERATIVE DISEASE; EPSTEIN BARR VIRUS INFECTION; FEVER; FLOW CYTOMETRY; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROA VACCINIFORME; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SKIN BIOPSY; SORE THROAT;

EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; HYDROA VACCINIFORME; KILLER CELLS, NATURAL; LYMPHOPROLIFERATIVE DISORDERS; MALE; T-LYMPHOCYTES;

EID: 84870010225     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181c036de     Document Type: Article

References (30)

1. Fafi-Kremer S, Morand P, Brion JP, et al. Long term shedding of infectious Epstein-Barr virus after infectious mononucleosis. J Infect Dis. 2005;191: 985-989.
2. Cho EY, Kim KH, Kim WS, et al. The spectrum of Epstein-Barr virusassociated lymphoproliferative disease in Korea: incidence of disease entities by age groups. J Korean Med Sci. 2008;23: 185-192.
3. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol. 2006;16: 251-261.
4. Ohshima K, Kimura H, Yoshino T, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int. 2008;58: 209-217.
5. Sato E, Ohga S, Kuroda H, et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol. 2008;83: 721-727.
6. Jeffrey IC. Infectious disease: EBV infections, including infectious mononucleosis. In: Fauci AS, Braunwald E, eds. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill; 2008: 1046-1048.
7. Mendoza N, Diamantis M, Arora A, et al. Mucocutaneous manifestations of Epstein-Barr virus infection. Am J Clin Dermatol. 2008;9: 295-305.
8. Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases. Semin Hematol. 2003;40: 124-132.
9. Suzuki K, Ohshima K, Karube K, et al. Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. Int J Oncol. 2004;24: 1165-1174.
10. Iwatsuki K, Ohtsuka M, Akiba H, et al. Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. J Am Acad Dermatol. 1999;40: 283-284.
11. Sawada A, Sato E, Koyama M, et al. NK-cell repertoire is feasible for diagnosing Epstein-Barr virus-infected NK-cell lymphoproliferative disease and evaluating the treatment effect. Am J Hematol. 2006;81: 576-581.
12. Gupta G, Man I, Kemmett D. Hydroa vacciniforme: a clinical and followup study of 17 cases. J Am Acad Dermatol. 2000;42: 208-213.
13. Goldgeier MH, Nordlund JJ, Lucky AW, et al. Hydroa vacciniforme: diagnosis and therapy. Arch Dermatol. 1982;118: 588-591.
14. Cho KH, Kim CW, Lee DY, et al. An Epstein-Barr virus-associated lymphoproliferative lesion of the skin presenting as recurrent necrotic papulovesicles of the face. Br J Dermatol. 1996;134: 791-796.
15. Iwatsuki K, Satoh M, Yamamoto T, et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol. 2006;142: 587-595.
16. Wu YH, Chen HC, Hsiao PF, et al. Hydroa vacciniforme-like Epstein-Barr virus-associated monoclonal T-lymphoproliferative disorder in a child. Int J Dermatol. 2007;46: 1081-1086.
17. Cho KH, Lee SH, Kim CW, et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol. 2004;151: 372-380.
18. Doeden K, Molina-Kirsch H, Perez E, et al. Hydroa-like lymphoma with CD56 expression. J Cutan Pathol. 2008;35: 488-494.
19. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. 2002;10: 7-14.
20. Feng S, Jin P, Zeng X. Hydroa vacciniforme-like primary cutaneous CD8- positive T-cell lymphoma. Eur J Dermatol. 2008;18: 364-365.
21. Cho KH, Kim CW, Heo DS, et al. Epstein-Barr virus-associated peripheral T-cell lymphoma in adults with hydroa vacciniforme-like lesions. Clin Exp Dermatol. 2001;26: 242-247.
22. Robinson RG. Abdominal complications of infectious mononucleosis. J Am Board Fam Pract. 1988;1: 207-210.
23. Doja A, Bitnun A, Ford Jones EL, et al. Pediatric Epstein-Barr virusassociated encephalitis: 10-year review. J Child Neurol. 2006;21: 384-391.
24. Caruso JM, Tung GA, Gascon GG, et al. Persistent preceding focal neurologic deficits in children with chronic Epstein-Barr virus encephalitis. J Child Neurol. 2000;15: 791-796.
25. Garefalakis K, Tsiodra P, Charalampopoulos A. Acute hemolytic anemia following infectious mononucleosis. Eur J Intern Med. 2007;18:260.
26. Iwatsuki K, Yamamoto T, Tsuji K. Hypersensitivity to mosquito bites and hydroa vacciniforme. Nippon Rinsho. 2006;64 (Suppl 3): 657-661.
27. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107: 3053-3057.
28. Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein- Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005;105: 994-996.
29. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110: 1123-1131.
30. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr- viruspositive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360: 436-442.